Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma

Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis. Moreover, the survival outcomes after failure of first-line therapy for unresectable HCC is still poor with limited...

詳細記述

書誌詳細

出版年:	Vaccines
主要な著者:	Mohamed A. Abd El Aziz, Antonio Facciorusso, Tarek Nayfeh, Samer Saadi, Mohamed Elnaggar, Christian Cotsoglou, Rodolfo Sacco
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2020-10-01
主題:	HCC CPI immunotherapy survival progression
オンライン･アクセス:	https://www.mdpi.com/2076-393X/8/4/616